At six and twelve months , the median seizure frequency for the original treatment group decreased by -2.39 seizures per month at 6 months ( -27.4 % ) and -3.03 seizures per month at 12 months ( -34.8 % ) , respectively , from the initial baseline ( p < 0.05 , signed-rank test ) .